Degradation of HPV20E6 by p53:: ΔNp63α and mutant p53R248W protect the wild type p53 mediated caspase-degradation

被引:11
|
作者
Fei, Jian-Wei [1 ]
de Villiers, Ethel-Michele [1 ]
机构
[1] Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, D-69120 Heidelberg, Germany
关键词
HPV20E6; wtp53; degradation; caspase; Delta Np63 alpha; mtp53R248W;
D O I
10.1002/ijc.23506
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The E6 and E7 proteins of human papillomaviruses (HPV) play a crucial role in the pathogenesis of malignant tumors. E6 protein of high-risk mucosal papillomaviruses targets a number of proteins for proteosomal degradation through complex formation with ubiquitin ligase E6AP. These proteins include, amongst others, p53, paxillin and PDZ-domain proteins e.g. Dig and MAGUK. The mechanism by which the E6 protein of cutaneous HPV types interacts with cellular proteins to induce either benign or malignant cutaneous lesions, has not been elucidated, although extensive ultraviolet exposure and mutated p53 (hot-spot mutations) are known to be associated with non-melanoma skin cancer. We demonstrate two mechanisms in which HPV20E6 may be involved in the infected cell. One pathway is the wtp53 mediated degradation of HPV20E6 through caspase-3. Mutated p53R248W and Delta Np63 alpha, as well as other unknown proteins involved in proteosome-dependent degradation, convey a protective effect on HPV20E6 under these conditions. This unveils a remarkable opposite regulation to the well-known mechanism of E6-E6AP mediated degradation of p53 for mucosal HPV types. In a second interaction, ectopically expressed HPV20E6 induces cleavage of procaspase-3 to active caspase-3. We demonstrate, in addition, in vivo binding of HPV20E6 to the intermediate filament vimentin. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:108 / 116
页数:9
相关论文
共 50 条
  • [31] Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Lu, Phong
    Vander Mause, Erica R.
    Bowman, Katherine E. Redd
    Brown, Sarah M.
    Ahne, Lisa
    Lim, Carol S.
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [32] Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Phong Lu
    Erica R. Vander Mause
    Katherine E. Redd Bowman
    Sarah M. Brown
    Lisa Ahne
    Carol S. Lim
    Journal of Ovarian Research, 12
  • [33] ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified
    WesierskaGadek, J
    BugajskaSchretter, A
    Cerni, C
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1996, 62 (01) : 90 - 101
  • [34] Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas
    Wu, Jianyuan
    Li, Qingdi Quentin
    Zhou, Huiping
    Lu, Yinying
    Li, Jueli M.
    Ma, Yao
    Wang, Li
    Fu, Tingting
    Gong, Xingjiang
    Weintraub, Michael
    Wu, Shuangchan
    Ding, Hong
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [35] Chaperoning of Mutant p53 Protein by Wild-type p53 Protein Causes Hypoxic Tumor Regression
    Gogna, Rajan
    Madan, Esha
    Kuppusamy, Periannan
    Pati, Uttam
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (04) : 2907 - 2914
  • [36] Transcription factor ZBP-89 stabilizes wild type p53 and a constitutively active p53 mutant
    Okada, M
    Merchant, JL
    GASTROENTEROLOGY, 2002, 122 (04) : A124 - A124
  • [37] Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas
    Jianyuan Wu
    Qingdi Quentin Li
    Huiping Zhou
    Yinying Lu
    Jueli M. Li
    Yao Ma
    Li Wang
    Tingting Fu
    Xingjiang Gong
    Michael Weintraub
    Shuangchan Wu
    Hong Ding
    Medical Oncology, 2014, 31
  • [38] Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells
    Fechner, G
    Perabo, FGE
    Schmidt, DH
    Haase, L
    Ludwig, E
    Schueller, H
    Blatter, J
    Müller, SC
    Albers, P
    UROLOGY, 2003, 61 (02) : 468 - 473
  • [39] Ceramide-rubusoside nanomicelles restores p53-mediated tumor suppression in p53R248W mutant ovarian cancer cells
    Khiste, Sachin K.
    Liu, Zhijun
    Liu, Yong-Yu
    CANCER RESEARCH, 2017, 77
  • [40] Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence
    Izumi Horikawa
    Kaori Fujita
    Lisa M Miller Jenkins
    Yukiharu Hiyoshi
    Abdul M. Mondal
    Borivoj Vojtesek
    David P. Lane
    Ettore Appella
    Curtis C. Harris
    Nature Communications, 5